The identification of volatile organic compounds (VOCs) in exhaled breath is a promising opportunity for noninvasive detection and prediction of treatment outcomes in patients with mesothelioma, according to data from a pilot study presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer, held … [Read more...]
Study Questions Use of Aggressive Surgery in Early Mesothelioma
Extended pleurectomy decortication combined with platinum and pemetrexed chemotherapy was associated with worse outcomes in patients with resectable mesothelioma compared with chemotherapy alone, according to a randomized trial. “As a surgeon, you have no idea how much it pains me to conclude that extended pleurectomy decortication — an … [Read more...]
Ozempic, Rybelsus, and Wegovy Use Might Cause Gastroparesis, Gastric Stasis, or Stomach Paralysis
In recent years we have seen an increasing number of adverse event reports for three Novo Nordisk semaglutide-containing drugs — Ozempic, Rybelsus, and Wegovy — that involve severe stomach conditions, including: Gastroparesis Gastric Stasis Stomach Paralysis The most common symptoms are nausea and vomiting, which can be severely … [Read more...]
Ozempic Gastric Side Effects: Gastroparesis, Stomach Paralysis, Intestinal Blockages
In the several years since Ozempic was approved by the FDA, there have been adverse event reports of Ozempic gastric side effects such as gastroparesis, stomach paralysis, and intestinal blockage cases in patients using Ozempic. Gastroparesis may also be called delayed gastric emptying. Gastroparesis is a long-term, chronic condition that can be … [Read more...]
Feladilimab by GSK for Malignant Pleural Mesothelioma: Likelihood of Approval
[ Feladilimab ] is under development [ by the pharmaceutical company GSK ] for the treatment of [ malignant pleural mesothelioma ], advanced solid tumors including non-small cell lung cancer, squamous non-small cell lung cancer, bladder cancer, cervical cancer, esophageal, urothelial cancer, clear renal cell carcinoma, head and neck cancer squamous … [Read more...]
Syfovre Eye Injections Adverse Reactions Update August 2023
We have some new information about Syfovre eye injections adverse reactions causing vision loss and blindness from Apellis Pharmaceuticals and the American Society of Retina Specialists (ASRS). Apellis Pharmaceuticals said that it has confirmed seven cases of Syfovre eye injections adverse reactions. More specifically, these Syfovre vision loss … [Read more...]
Occupational exposure to cosmetic talc and mesothelioma in barbers, hairdressers, and cosmetologists: A systematic review of the epidemiology
Inhalation exposure to cosmetic talc has generated much scientific debate regarding its potential as a risk factor for mesothelioma, a rare, but fatal cancer. Barbers, hairdressers, and cosmetologists have regularly used cosmetic talc-containing products, but the collective epidemiological evidence for mesothelioma in these occupations has yet to … [Read more...]
Tepezza-Related Hearing Problems Warning July 2023
A warning about the risks of Tepezza-related hearing problems was finally added with a Tepezza drug label change in July 2023. Some of the various hearing problems associated with Tepezza can cause hearing loss and can be permanent. In more detail, in the current Tepezza Full Prescribing Information (Revised: July 2023) document, we point out … [Read more...]
Malignant Pleural Mesothelioma (MPM) Presenting as Hydropneumothorax
An 86-year-old man presented with bilateral lower limb edema and was found to have hydropneumothorax on chest radiography. CT revealed a substantial pleural effusion and plaques. The patient had a history of working in a stone workshop, but the extent of asbestos exposure remained unknown. Thoracic drainage and subsequent thoracoscopic surgery … [Read more...]
Syfovre-related Vision Loss Reported In Patients After Their First Injection
Syfovre-related vision loss has been reported in patients after the first time they used a Syfovre injection treatment for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). In mid-July 2023 the American Society of Retinal Specialists (ASRS) issued a warning letter about Syfovre-related vision loss as well as some other … [Read more...]
- « Previous Page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- …
- 21
- Next Page »